Showing 4211-4220 of 5911 results for "".
- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem Cellshttps://modernod.com/news/nei-scientists-publish-recipe-for-making-blood-vessel-cells-from-patient-stem-cells/2481626/Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. &ldquo
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo
- International Sports Vision Association Launches "Ask a Sports Vision Expert" Featurehttps://modernod.com/news/international-sports-vision-association-launches-ask-a-sports-vision-expert-feature/2481622/A growing body of evidence confirms that visual abilities can be strengthened and enhanced by means of appropriate visual training. Sports vision, the science of helping athletes reach peak levels of performance through enhancement of visual skills, is becoming more important in training for all
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrackhttps://modernod.com/news/c-light-receives-fda-clearance-for-retinal-eye-movement-monitor-retitrack/2481615/C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals. The
- Oculus Incorporates New Subsidiary in Indiahttps://modernod.com/news/oculus-incorporates-new-subsidiary-in-india/2481614/Oculus has incorporated Oculus Medical Devices India as its 12th international subsidiary as of May 1, 2023. Located in Mumbai, Oculus India, aims to provide cutting-edge medical equipment to the Indian market while maintaining the high standards and quality that Oculus is known for. Sr
- New Museum of the Eye Exhibit Explores the Eye as a Cultural Symbol, From Ancient to Modern Timeshttps://modernod.com/news/new-museum-of-the-eye-exhibit-explores-the-eye-as-a-cultural-symbol-from-ancient-to-modern-times/2481612/Truhlsen-Marmor Museum of the Eye, the world’s only free, public museum dedicated to the science of sight, announced the opening of "Decoding the Eye: Signs and Symbols," a new exhibit exploring how the eye appears as a symbol throughout time. The exhibit will run from May 2023 to
- Eyenovia Receives FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasishttps://modernod.com/news/eyenovia-receives-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis/2481603/Eyenovia announced that the FDA has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combinatio
- Cassini Launches Cassini Connect Digital Cataract Surgery Suitehttps://modernod.com/news/cassini-launches-cassini-connect-digital-cataract-surgery-suite/2481601/Cassini announced the launch of the Cassini Connect, a digital cataract surgery suite compatible with most leading microscope brands, at the 2023 ASCRS meeting. Cassini Connect offers an integrated cataract surgery workflow and data solution, from pre-op